GLP-1 medications linked to 36% lower colorectal cancer risk

Colorectal cancer kills around 53,000 Americans every year and is the third most common cancer in the US. Aspirin has long been studied as a preventive agent - but its bleeding risks made it a difficult recommendation for most people. A large new analysis presented at ASCO 2026 suggests GLP-1 medications may offer a safer and more effective alternative. GLP-1 users were 36% less likely to develop colorectal cancer than aspirin users across a matched dataset of 281,656 people - a finding with significant public health implications if it holds in randomised trials.

TL;DR

A 281,656-person ASCO 2026 study found GLP-1 users 36% less likely to develop colorectal cancer than aspirin users, rising to 42% lower risk in high-risk individuals. Semaglutide, liraglutide, and dulaglutide all showed significant effects; tirzepatide did not. The benefit does not extend to tobacco users or people with atherosclerosis. This is observational data - not proof GLP-1 drugs prevent cancer.

What the ASCO 2026 study found

The analysis, presented by Dr Colton Jones at the 2026 ASCO Gastrointestinal Cancers Symposium (Abstract 18), drew on the TriNetX research network covering 281,656 participants - 140,828 matched per cohort. Mean age was 58 years, 69% female, and median follow-up was 2,153 days for GLP-1 users and 1,743 days for aspirin users.

The key finding: people taking GLP-1 receptor agonists were 36% less likely to develop colorectal cancer compared to those taking aspirin for cancer prevention. Among individuals already at high risk - defined by having a prior diagnosis of colorectal polyps, inflammatory bowel disease, or family history - the risk reduction reached 42-43%.

Dr Jones put the clinical significance plainly: "GLP-1 receptor agonists, now widely prescribed for diabetes and obesity, may offer a safer option for both metabolic control and cancer prevention." Dr Joel Saltzman of ASCO added that the findings show these drugs "may be an important part of cancer prevention strategies as well."

Which GLP-1 medications showed the effect - and which did not

The drug-by-drug breakdown is one of the most important details in this study. Not all GLP-1 receptor agonists showed a significant colorectal cancer risk reduction:

• Semaglutide (Ozempic, Wegovy) - significant reduction in colorectal cancer risk
• Liraglutide (Victoza, Saxenda) - significant reduction
• Dulaglutide (Trulicity) - significant reduction
• Tirzepatide (Mounjaro, Zepbound) - no significant effect observed
• Exenatide (Byetta, Bydureon) - no significant effect observed

The absence of an effect with tirzepatide is an important nuance. Tirzepatide is now the most prescribed injectable GLP-1 medication in the US. Its dual GLP-1 and GIP mechanism differs from the pure GLP-1 agonists that showed the signal. Researchers note this may reflect the different molecular mechanisms, different patient populations prescribed each drug, or the shorter follow-up time available for tirzepatide data. Longer-term tirzepatide datasets will be needed to understand whether the colorectal cancer signal extends to this drug class.

Who does not benefit

The risk reduction was not seen in all subgroups. Two notable exceptions:

• Current tobacco users - GLP-1 users who smoked showed no significant colorectal cancer risk reduction compared to aspirin users. Smoking's carcinogenic effects on the colorectal mucosa may overwhelm the benefit of GLP-1 therapy on inflammatory and metabolic pathways.
• People with atherosclerosis - this group also did not show a statistically significant benefit. The mechanisms are not yet understood, but this may reflect a distinct biological context in which the anti-inflammatory effects of GLP-1 drugs operate differently.

GLP-1 users under 45 years of age did show a significant benefit - relevant given the well-documented rise in early-onset colorectal cancer in younger adults over the past two decades.

The absolute risk numbers matter too

Relative risk reductions can be misleading without context. The absolute benefit here is modest at an individual level: researchers estimated that over 2,000 people would need to take a GLP-1 medication for one colorectal cancer case to be prevented. This "number needed to treat" is similar to aspirin's cancer prevention figures from earlier meta-analyses.

The population-level implication is different. Colorectal cancer affects approximately 154,270 Americans per year. If 6% of US adults - the current GLP-1 prescription rate - are on these medications long-term, even a modest per-person risk reduction translates to thousands of cases prevented annually. Dr Saltzman estimated the public health impact could be substantial "given the prevalence of GLP-1 medication use and the high incidence of colorectal cancer."

Why GLP-1 medications might reduce colorectal cancer risk

The mechanism is not fully established, but researchers have proposed several plausible pathways:

Reduced insulin and IGF-1 signalling

Insulin and insulin-like growth factor 1 (IGF-1) are potent cell proliferation signals. Chronically elevated insulin - common in obesity and type 2 diabetes - has been linked to higher colorectal cancer risk in multiple cohort studies. GLP-1 medications lower fasting insulin and improve insulin sensitivity substantially. Reducing the proliferative drive from the insulin axis may directly lower the rate at which colorectal cells divide into cancerous patterns.

Chronic inflammation reduction

Chronic low-grade inflammation is a well-established driver of colorectal cancer progression. GLP-1 medications reduce systemic inflammatory markers including C-reactive protein, TNF-alpha, and IL-6 as adipose tissue decreases. A less inflammatory colonic environment may be less hospitable to tumour initiation and progression.

Weight loss effects on colonic microenvironment

Obesity is independently associated with higher colorectal cancer risk, partly through higher oestrogen levels and altered bile acid metabolism that affect the colonic lining. Weight loss changes this microenvironment - reducing circulating oestrogen, normalising bile acid profiles, and reducing the mechanical pressure on the colonic mucosa associated with intra-abdominal fat.

Direct GLP-1 receptor effects in colonic tissue

GLP-1 receptors are expressed in colorectal tissue. Early findings from preclinical research suggest direct GLP-1 receptor activation may inhibit proliferation of colorectal tumour cells through cAMP-mediated pathways. This remains an active area of research and has not yet been confirmed in large human studies.

What this means for people currently on GLP-1 medications

This data does not change any current clinical recommendation. GLP-1 medications are not prescribed for cancer prevention, and this single observational analysis does not establish a causal relationship. What it does establish is a consistent, statistically significant signal across a large dataset - one that warrants further investigation in randomised trials.

If you are on semaglutide, liraglutide, or another GLP-1 receptor agonist, this study suggests you may be receiving a potential colorectal cancer risk reduction as an unintended benefit - particularly if you are in a high-risk group. Screening remains essential regardless. A 36% risk reduction still leaves substantial residual risk, and colonoscopy or stool testing at guideline-recommended intervals is not replaced by GLP-1 therapy.

Supporting your gut health on GLP-1 medications

The colonic microbiome plays an active role in cancer risk. Multiple studies now show that GLP-1 medications reshape gut bacteria composition - increasing Akkermansia and Bifidobacterium species associated with reduced inflammation and improved gut barrier function. The nutritional status of the gut lining depends on adequate folate, vitamin B12, and antioxidant vitamins C and E - all of which can be depleted when food intake drops substantially on GLP-1 therapy.

GLP-1 Shield is formulated around the nutrient gaps that GLP-1 medications create, including the B vitamins and antioxidants that your gut tissue needs to maintain integrity and healthy cell turnover.

Frequently asked questions

Does Ozempic prevent colorectal cancer?

The ASCO 2026 analysis found a 36% lower colorectal cancer risk in GLP-1 users vs aspirin users, but this is observational data - not a randomised trial confirming prevention. GLP-1 medications are not approved or prescribed for cancer prevention. The finding is a promising signal that needs confirmation in randomised controlled trials before any clinical recommendations change.

Does tirzepatide (Mounjaro, Zepbound) also reduce colorectal cancer risk?

In this ASCO 2026 dataset, tirzepatide did not show a statistically significant colorectal cancer risk reduction, while semaglutide, liraglutide, and dulaglutide did. Researchers note this may reflect the different molecular mechanism of tirzepatide, shorter follow-up data, or differences in study populations. Longer-term tirzepatide data is needed to answer this definitively.

Should I get a colonoscopy if I am on a GLP-1 medication?

Yes. A potential risk reduction from GLP-1 therapy does not replace guideline-recommended colorectal cancer screening. Current US guidelines recommend colonoscopy starting at age 45 for average-risk adults, earlier for high-risk individuals. Your GLP-1 medication does not change this schedule.

Why might GLP-1 drugs reduce cancer risk but not tirzepatide?

Tirzepatide is a dual GLP-1 and GIP receptor agonist, while semaglutide and liraglutide are pure GLP-1 agonists. The cancer risk reduction signal may be specifically linked to GLP-1 receptor signalling in colorectal tissue, or to molecular pathways activated by GLP-1 alone but not by the combined GLP-1/GIP mechanism. This remains an active area of research.